Bilateral TMS vs. Unilateral TMS (biTMSvsuniTMS)

• ClinicalTrials.gov Identifier: NCT03710967
• Recruitment Status: Unknown
• First Posted: October 18, 2018
• Last Update Posted: October 18, 2018
• Sponsor: Radboud University Medical Center
• Information provided by (Responsible Party): Radboud University Medical Center

Study Description

Brief Summary:

Rationale: In 2016, Henssen et al. discuss that orofacial pain may be conducted in a bilateral fashion, inducing activation of both thalami [1]. For this reason, bilateral stimulation of the motor cortex is thought to induce a stronger analgesic effect compared to unilateral motor cortex stimulation by transcranial magnetic stimulation.

Objective: To investigate the superiority of bilateral transcranial magnetic stimulation (TMS) over unilateral TMS of the motor cortex Study design: Double-blind, randomized controlled trial Study population: Patients that suffer from chronic orofacial pain and have not been treated (yet) with any form of neuromodulation.

Intervention (if applicable): One group receives bilateral TMS whereas the other group receives unilateral TMS for one month. After one month, the groups switch treatment protocol.

Main study parameters/endpoints: Modification in intensity of pain as measured using the VAS, the influence the relief of pain with regard to quality of life and daily activities using the McGill Pain Questionnaire.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Time investment of patients.

Condition or disease	Intervention/treatment	Phase
Neuropathic Pain; Orofacial Pain; Trigeminal Neuropathy	Device: Transcranial magnetic stimulation	Not Applicable

Detailed Description:

For this study, we aim to include 12 patients with intractable, chronic orofacial pain of peripheral origin with a baseline VAS of at least 5 (0= no pain, 10= worst possible pain). The investigator (Dylan Henssen) contacts the pain nurse, neurosurgeons and pain physicians to ask them to seek contact with their patients to inform them about this research. Afterwards, if the patients wish to learn more or wish to participate, they receive an information package, including an information letter and an informed consent form. When the patient agrees to be included they receive four McGill Pain questionnaires which must be filled in weekly. After these four weeks, the patient is invited to the outpatient clinic to meet with the investigator. During this consultation, the patient talks about the pain he/she experiences, submits the four filled-in questionnaires and receives further information about the research. After the consultation, all patients are randomized in double-blinded fashion.

At the next meeting at the Donders Institute at Nijmegen, the patient takes place in a relaxing chair. A second, independent researcher will install the transcranial magnetic stimulation (TMS) coils, one on each side of the patient. The coils are positioned in such a fashion that both the coils can stimulate the primary motor cortex. Then the independent researcher starts the stimulation protocol. In the first session, the patient either receives unilateral or bilateral stimulation. After this session, the patient fills in a new McGill Pain questionnaire in order to measure the pain sensation after the first session of TMS. Then the patient goes home for one month. At home, another 4 McGill Pain Questionnaires are asked to fill in. After this, the patient returns to the Donders Institute to take place in the relaxing chair in order to be treated in the second session. Again, the patient either receives unilateral or bilateral stimulation, depending on what was received during the first session. Again, the patients are asked to fill in 4 new McGill Pain questionnaires, one per week (See figure 1).

At the end of this session, the patient is invited to meet with the investigator or independent researcher once more to talk about their experiences and pain relief during the research. This interview takes place at Radboudumc and is audio recorded.

All the McGill Pain questionnaires are analyzed by the researcher (Dylan Henssen) using SPSS. Afterwards, the independent researcher discloses which patient received uni- or bilateral in which order. The audio recorded interviews are transcribed verbatim and analyzed using Atlas.tii.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 12 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: single-blinded, randomized controlled cross-over design trial
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Bilateral vs. Unilateral Transcranial Magnetic Stimulation of the Primary Motor Cortex to Treat Chronic Orofacial Pain: a Pilot Study With a Randomized Controlled Design
• Actual Study Start Date: May 1, 2018
• Estimated Primary Completion Date: December 31, 2018
• Estimated Study Completion Date: September 1, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bilateral TMS	Device: Transcranial magnetic stimulation; Transcranial magnetic stimulation of the primary motor cortex
Active Comparator: Unilateral TMS	Device: Transcranial magnetic stimulation; Transcranial magnetic stimulation of the primary motor cortex

Outcome Measures

Primary Outcome Measures :

1. Pain intensity [ Time Frame: 8 weeks ]
   Visual analogue scale

Secondary Outcome Measures :

1. Medication intake [ Time Frame: 8 weeks ]
   Medication quantification scale
2. Quality of life [ Time Frame: 8 weeks ]
   McGill Pain Questionnaire: Quality of life index
3. Pain descriptor [ Time Frame: 8 weeks ]
   McGill Pain Questionnaire: Pain descriptors

Other Outcome Measures:

1. Patient global improvement scale [ Time Frame: 8 weeks ]
   PGIC
2. Qualitative assessment [ Time Frame: 8 weeks ]
   Face-to-face interviews

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Suffering from painful trigeminal neuropathy according to the International Classification of Headache Disorder (ICHD), 3rd beta version;
2. Mean pain-intensity scores at baseline needed to be greater than 50mm as measured by the visual analogue scale (VAS);
3. Aged between 18-80 years old;
4. Non-pregnant, non-lactating and not planned to become pregnant during the study;
5. Capable of completing headache pain self-assessments;
6. Agrees not to change any medication or dosages in relation to the painful trigeminal neuropathy during the study

Exclusion Criteria:

Patients were excluded from this study when they suffered from other neurological diseases (i.e., multiple sclerosis or epilepsy) or other chronic pain conditions or had a history of intracranial aneurysm, intracranial hemorrhage, brain tumor, or significant head trauma. Other exclusion criteria concerned patients having a pacemaker, intracardial device, neuromodulation device or other forms of metal implants in the craniocervical region. Finally, only patients who did not undergo any form of TMS prior to this experiment were included.

Contacts and Locations

Locations

Netherlands

Radboud University

Nijmegen, Gelderland, Netherlands, 6500HB

Sponsors and Collaborators

Radboud University Medical Center

Investigators

• Principal Investigator: Dylan Henssen, MD; RadboudUniversity

More Information

• Responsible Party: Radboud University Medical Center
• ClinicalTrials.gov Identifier: NCT03710967
• Other Study ID Numbers: NL62849.091.17
• First Posted: October 18, 2018
• Last Update Posted: October 18, 2018
• Last Verified: June 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Trigeminal Nerve Diseases; Neuralgia; Facial Pain; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Facial Neuralgia; Facial Nerve Diseases; Mouth Diseases; Stomatognathic Diseases; Cranial Nerve Diseases